Red Blood Cell Aggregation in Preterm and Term Neonates and Adults
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Red Blood Cell Rheology in Sepsis K
M. Piagnerelli Red blood cell rheology in sepsis K. Zouaoui Boudjeltia M. Vanhaeverbeek J.-L. Vincent Abstract Changes in red blood cell membrane components such as sialic (RBC) function can contribute to acid, and an increase in others such alterations in microcirculatory blood as 2,3 diphosphoglycerate. Other flow and cellular dysoxia in sepsis. factors include interactions with Decreases in RBC and neutrophil white blood cells and their products deformability impair the passage of (reactive oxygen species), or the these cells through the microcircula- effects of temperature variations. tion. While the role of leukocytes Understanding the mechanisms of has been the focus of many studies altered RBC rheology in sepsis, and in sepsis, the role of erythrocyte the effects on blood flow and oxygen rheological alterations in this syn- transport, may lead to improved drome has only recently been inves- patient management and reductions tigated. RBC rheology can be influ- in morbidity and mortality. enced by many factors, including alterations in intracellular calcium Keywords Erythrocyte · and adenosine triphosphate (ATP) Deformability · Nitric oxide · concentrations, the effects of nitric Sialic acid · Multiple organ failure · oxide, a decrease in some RBC Oxygen transport Introduction ogy of microcirculatory alterations and, perhaps, the treatment of sepsis. Severe sepsis and septic shock are the commonest causes This review evaluates alterations occurring in RBC of death in intensive care units (ICUs), with associated rheology during sepsis and possible underlying mecha- mortality rates of 30–50% [1]. Sepsis is a complex nisms. The potential implications of blood transfusion pathophysiological process that involves both alterations and erythropoietin administration in sepsis will not be in the microcirculation and changes in the biochemical discussed. -
Effect of Intake of Food Hydrocolloids of Bacterial Origin on the Glycemic Response in Humans: Systematic Review and Narrative Synthesis
nutrients Review Effect of Intake of Food Hydrocolloids of Bacterial Origin on the Glycemic Response in Humans: Systematic Review and Narrative Synthesis Norah A. Alshammari 1,2, Moira A. Taylor 3, Rebecca Stevenson 4 , Ourania Gouseti 5, Jaber Alyami 6 , Syahrizal Muttakin 7,8, Serafim Bakalis 5, Alison Lovegrove 9, Guruprasad P. Aithal 2 and Luca Marciani 2,* 1 Department of Clinical Nutrition, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia; [email protected] 2 Translational Medical Sciences and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham NG7 2UH, UK; [email protected] 3 Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham NG7 2UH, UK; [email protected] 4 Precision Imaging Beacon, University of Nottingham, Nottingham NG7 2UH, UK; [email protected] 5 Department of Food Science, University of Copenhagen, DK-1958 Copenhagen, Denmark; [email protected] (O.G.); [email protected] (S.B.) 6 Department of Diagnostic Radiology, Faculty of Applied Medical Science, King Abdulaziz University (KAU), Jeddah 21589, Saudi Arabia; [email protected] 7 Indonesian Agency for Agricultural Research and Development, Jakarta 12540, Indonesia; Citation: Alshammari, N.A.; [email protected] Taylor, M.A.; Stevenson, R.; 8 School of Chemical Engineering, University of Birmingham, Birmingham B15 2TT, UK Gouseti, O.; Alyami, J.; Muttakin, S.; 9 Rothamsted Research, Harpenden, Hertfordshire AL5 2JQ, UK; [email protected] Bakalis, S.; Lovegrove, A.; Aithal, G.P.; * Correspondence: [email protected]; Tel.: +44-115-823-1248 Marciani, L. -
Canine Immune-Mediated Hemolytic Anemia – Brief Review
TRADITION AND MODERNITY IN VETERINARY MEDICINE, 2018, vol. 3, No 1(4): 59–64 CANINE IMMUNE-MEDIATED HEMOLYTIC ANEMIA – BRIEF REVIEW Iliyan Manev1, Victoria Marincheva2 1University of Forestry, Faculty of Veterinary Medicine, Sofia, Bulgaria 2Animal Rescue, Sofia, Bulgaria E-mail: [email protected] ABSTRACT Immune-mediated hemolytic anemia (IMHA) is a common autoimmune disorder in dogs. It affects both sexes but occurs more often in female, middle-aged animals. IMHA can be idiopathic (primary) or secondary to infectious, neoplastic and autoimmune disorders. There is an acute regenerative anemia with accompanying hypoxia. Destruction of erythrocytes can be intravascular (as a result of complement system activation) or extravascular (removal of antibody-coated red blood cells by the macrophages in the liver and spleen). Diag- nosis is based on the presence of anemia, in vitro autoagglutination, positive direct antiglobulin test (Coomb`s test), detection of spherocytes. It is crucial to exclude possible secondary causes. The treatment protocol aims to cease cell destruction by high doses of corticosteroids, aggressive supportive care and long-term application of immunosuppressive drug combinations. Still lethality is high because of complications (pulmonary throm- boembolism, DIC), medication resistance, relapses. Key words: immune-mediated, anemia, canine, hemolysis, immunosuppressive drugs. Immune-mediated hemolytic anemia is one of the commonly diagnosed canine autoimmune diseases and a model of acute and clinically relevant anemia. Impaired -
Differential Effects of the Poly (ADP-Ribose)Polymerase (PARP
British Journal of Cancer (2001) 84(1), 106–112 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1555, available online at http://www.idealibrary.com on http://www.bjcancer.com Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro KJ Bowman*, DR Newell, AH Calvert and NJ Curtin Cancer Research Unit, University of Newcastle upon Tyne Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK Summary The potent novel poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025, enhances the cytotoxicity of DNA-methylating agents and ionizing radiation by inhibiting DNA repair. We report here an investigation of the role of PARP in the cellular responses to inhibitors of topoisomerase I and II using NU1025. The cytotoxicity of the topoisomerase I inhibitor, camptothecin, was increased 2.6-fold in L1210 cells by co-incubation with NU1025. Camptothecin-induced DNA strand breaks were also increased 2.5-fold by NU1025 and exposure to camptothecin-activated PARP. In contrast, NU1025 did not increase the DNA strand breakage or cytotoxicity caused by the topoisomerase II inhibitor etoposide. Exposure to etoposide did not activate PARP even at concentrations that caused significant levels of apoptosis. Taken together, these data suggest that potentiation of camptothecin cytotoxicity by NU1025 is a direct result of increased DNA strand breakage, and that activation of PARP by camptothecin-induced DNA damage contributes to its repair and consequently cell survival. However, in L1210 cells at least, it would appear that PARP is not involved in the cellular response to etoposide-mediated DNA damage. -
(12) Patent Application Publication (10) Pub. No.: US 2012/0028333 A1 Piatesi Et Al
US 20120028333A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0028333 A1 Piatesi et al. (43) Pub. Date: Feb. 2, 2012 (54) USE OF ENZYMES TO REDUCE ALDEHYDES (30) Foreign Application Priority Data FROMALDEHYDE-CONTAINING PRODUCTS Apr. 7, 2009 (EP) .................................. O9157522.5 Publication Classification (76) Inventors: Andrea Piatesi, Mannheim (DE); (51) Int. Cl. Tilo Habicher, Speyer (DE); CI2N 9/02 (2006.01) Michael Bischel, Worms (DE); CI2N I/00 (2006.01) Li-Wen Wang, Mannheim (DE): CI2N 15/63 (2006.01) Jirgen Reichert, Limburgerhof A62D 3/02 (2007.01) (DE); Rainer Packe-Wirth, C7H 2L/04 (2006.01) Trostberg (DE); Kai-Uwe (52) U.S. Cl. ... 435/189: 435/262:536/23.2:435/320.1; Baldenius, Heidelberg (DE); Erich 435/243 Kromm, Weisenheim am Sand (57) ABSTRACT (DE); Stefan Häfner, Speyer (DE); Carsten Schwalb. Mannheim (DE); The invention relates to the use of an enzyme preparation Hans Wolfgang Höffken, which catalyzes the degradation of formaldehyde for reduc Ludwigshafen (DE) ing the formaldehyde content in a formaldehyde-containing formulation. In a preferred embodiment, the enzyme prepa ration contains a formaldehyde dismutase from a Pseudomo (21) Appl. No.: 13/262,662 nas putida Strain. Further, the invention refers to a process for reducing the formaldehyde content in cross-linking agents for textile finishing or in polymer dispersions used, e.g. in con (22) PCT Filed: Mar. 31, 2010 struction chemistry. Further the invention relates to the use of an enzyme preparation which catalyzes the degradation of (86). PCT No.: PCT/EP1OAS4284 aldehydes for reducing the formaldehyde content in an alde hyde-containing formulation. -
Selection of Cryoprotectant in Lyophilization of Progesterone-Loaded Stearic Acid Solid Lipid Nanoparticles
pharmaceutics Article Selection of Cryoprotectant in Lyophilization of Progesterone-Loaded Stearic Acid Solid Lipid Nanoparticles Timothy M. Amis, Jwala Renukuntla, Pradeep Kumar Bolla and Bradley A. Clark * Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27268, USA; [email protected] (T.M.A.); [email protected] (J.R.); [email protected] (P.K.B.) * Correspondence: [email protected]; Tel.: +1-336-841-9665 Received: 18 August 2020; Accepted: 16 September 2020; Published: 19 September 2020 Abstract: Cryoprotectants are often required in lyophilization to reduce or eliminate agglomeration of solute or suspended materials. The aim of this study was to select a cryoprotecting agent and optimize its concentration in a solid lipid nanoparticle formulation. Progesterone-loaded stearic acid solid lipid nanoparticles (SA-P SLNs) were prepared by hot homogenization with high speed mixing and sonication. The stearic acid content was 4.6% w/w and progesterone was 0.46% w/w of the initial formulation. Multiple surfactants were evaluated, and a lecithin and sodium taurocholate system was chosen. Three concentrations of surfactant were then evaluated, and a concentration of 2% w/w was chosen based on particle size, polydispersity, and zeta potential. Agglomeration of SA-P SLNs after lyophilization was observed as measured by increased particle size. Dextran, glycine, mannitol, polyvinylpyrrolidone (PVP), sorbitol, and trehalose were evaluated as cryoprotectants by both an initial freeze–thaw analysis and after lyophilization. Once selected as the cryoprotectant, trehalose was evaluated at 5%, 10%, 15%, and 20% for optimal concentration, with 20% trehalose being finally selected as the level of choice. -
Canine Multiple Myeloma
Canine Multiple Myeloma Meredith Maczuzak, DVM; Kenneth S. Latimer, DVM, PhD; Paula M. Krimer, DVM, DVSc; and Perry J. Bain, DVM, PhD Class of 2003 (Maczuzak) and Department of Pathology (Latimer, Krimer, Bain), College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7388 Introduction Multiple myeloma or plasma cell myeloma, is a neoplasm of well- differentiated B cell lymphocytes typically originating from the bone marrow. Neoplastic cells can metastasize widely, having a predilection for bone and resulting in osteolysis. The malignant transformation of a single B cell can secrete a homogenous immunoglobulin product known as paraprotein, which will mimic the structure of normal immunoglobulins. Overabundant production of paraprotein, consisting of any of the immunoglobulin classes, will appear as a sharp, well-defined peak or monoclonal gammopathy on serum electrophoresis. The most frequently encountered multiple myelomas secrete IgG or IgA paraproteins, however IgM myelomas (macroglobulinemia) have also been diagnosed in companion animals. Light chain disease is caused by plasma cell overproduction of the light chain segment of the immunoglobulin complex, consisting of either the lambda or kappa light chain. These proteins are referred to as Bence-Jones proteins and are the most commonly observed immunoglobulin fragments in the monoclonal gammopathies.2 There are rare instances where a malignant plasma cell neoplasm will be nonsecretory. These tumors occur in approximately 1% of all cases of multiple myeloma and are referred -
6) Dextran Antibody → Behavior of an Anti
Position Effects of Variable Region Carbohydrate on the Affinity and In Vivo Behavior of an Anti-(1→6) Dextran Antibody This information is current as M. Josefina Coloma, Ryan K. Trinh, Alexander R. Martinez of September 27, 2021. and Sherie L. Morrison J Immunol 1999; 162:2162-2170; ; http://www.jimmunol.org/content/162/4/2162 Downloaded from References This article cites 45 articles, 14 of which you can access for free at: http://www.jimmunol.org/content/162/4/2162.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 27, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Position Effects of Variable Region Carbohydrate on the Affinity and In Vivo Behavior of an Anti-(136) Dextran Antibody1 M. Josefina Coloma, Ryan K. Trinh, Alexander R. Martinez, and Sherie L. Morrison2 IgG is a glycoprotein with an N-linked carbohydrate structure attached to the CH2 domain of each of its heavy chains. -
Complete Blood Count in Primary Care
Complete Blood Count in Primary Care bpac nz better medicine Editorial Team bpacnz Tony Fraser 10 George Street Professor Murray Tilyard PO Box 6032, Dunedin Clinical Advisory Group phone 03 477 5418 Dr Dave Colquhoun Michele Cray free fax 0800 bpac nz Dr Rosemary Ikram www.bpac.org.nz Dr Peter Jensen Dr Cam Kyle Dr Chris Leathart Dr Lynn McBain Associate Professor Jim Reid Dr David Reith Professor Murray Tilyard Programme Development Team Noni Allison Rachael Clarke Rebecca Didham Terry Ehau Peter Ellison Dr Malcolm Kendall-Smith Dr Anne Marie Tangney Dr Trevor Walker Dr Sharyn Willis Dave Woods Report Development Team Justine Broadley Todd Gillies Lana Johnson Web Gordon Smith Design Michael Crawford Management and Administration Kaye Baldwin Tony Fraser Kyla Letman Professor Murray Tilyard Distribution Zane Lindon Lyn Thomlinson Colleen Witchall All information is intended for use by competent health care professionals and should be utilised in conjunction with © May 2008 pertinent clinical data. Contents Key points/purpose 2 Introduction 2 Background ▪ Haematopoiesis - Cell development 3 ▪ Limitations of reference ranges for the CBC 4 ▪ Borderline abnormal results must be interpreted in clinical context 4 ▪ History and clinical examination 4 White Cells ▪ Neutrophils 5 ▪ Lymphocytes 9 ▪ Monocytes 11 ▪ Basophils 12 ▪ Eosinophils 12 ▪ Platelets 13 Haemoglobin and red cell indices ▪ Low haemoglobin 15 ▪ Microcytic anaemia 15 ▪ Normocytic anaemia 16 ▪ Macrocytic anaemia 17 ▪ High haemoglobin 17 ▪ Other red cell indices 18 Summary Table 19 Glossary 20 This resource is a consensus document, developed with haematology and general practice input. We would like to thank: Dr Liam Fernyhough, Haematologist, Canterbury Health Laboratories Dr Chris Leathart, GP, Christchurch Dr Edward Theakston, Haematologist, Diagnostic Medlab Ltd We would like to acknowledge their advice, expertise and valuable feedback on this document. -
8 Erythrocyte Sedimentation Rate (Esr)
MODULE Erythrocyte Sedimentation Rate (ESR) Hematology and Blood Bank Technique 8 Notes ERYTHROCYTE SEDIMENTATION RATE (ESR) 8.1 INTRODUCTION Erythryocyte Sedimentation Rate (ESR) is the measurement after 1hour of the sedimentation of red cells when blood is allowed to stand in an open ended glass tube mounted vertically on a stand. OBJECTIVES After reading this lesson, you will be able to: z describe the methods used for measuring ESR z enlist the factors influencing the sedimentation of red cells z discuss the significance of measuring ESR z describe the reticulocyte count and it’s significance 8.2 METHODS OF MEASURING ESR ESR can be measured in the laboratory by two methods z Westergren method z Automated ESR analyser The International Council for Standardization in Hematology recommends the use of Westergren method as the standard method for measuring ESR. Westergren method The Westergren pipette is a glass pipette 30 cm in length and 2.5mm in diameter. The bore is uniform to within 5% throughout. A graduated scale in mm extends over the lower 20 cm. 62 HEMATOLOGY AND BLOOD BANK TECHNIQUE Erythrocyte Sedimentation Rate (ESR) MODULE Sample: Venous blood collected in EDTA. Four volumes of blood is diluted in Hematology and Blood 1 volume of citrate. Alternatively, 2ml blood is directly collected in 0.5ml of Bank Technique 3.8% trisodium citrate. Equipment required 1. Westergren pipette 2. Stainless steel rack for holding pipette Notes 3. Timer Method 1. Mix the blood sample well and draw in the Westergren pipette to the 0mm mark with a rubber teat. 2. Place the tube exactly vertical in the rack which has a rubber cork at the bottom. -
Physical Charaterization of Red Blood Cell Aggregation Daniel Amadeus Dominic Flormann
Physical charaterization of red blood cell aggregation Daniel Amadeus Dominic Flormann To cite this version: Daniel Amadeus Dominic Flormann. Physical charaterization of red blood cell aggregation. Biological Physics [physics.bio-ph]. Universität des Saarlandes, 2017. English. NNT : 2017GREAY002. tel- 01577838 HAL Id: tel-01577838 https://tel.archives-ouvertes.fr/tel-01577838 Submitted on 28 Aug 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE LA COMMUNAUTÉ UNIVERSITÉ GRENOBLE ALPES préparée dans le cadre d’une cotutelle entre la Communauté Université Grenoble Alpes et l’Universität des Saarlandes Spécialité : Physique pour les sciences du vivant Arrêté ministériel : 25 mai 2016 Présentée par Daniel Amadeus Dominic Flormann Thèse dirigée par M. Thomas Podgorski et M. Christian Wagner préparée au sein du Laboratoire Interdisciplinaire de Physique, Grenoble et de Experimentalphysik, Saarbrücken dans les Écoles doctorales de Physique de l’Université Grenoble Alpes et de Dekanat der Universität des Saarlandes -
Successful Autologous Peripheral Blood Stem Cell Harvest and Transplantation After Splenectomy in a Patient with Multiple Myeloma with Hereditary Spherocytosis
International Journal of Myeloma 8(3): 11–15, 2018 CASE REPORT ©Japanese Society of Myeloma Successful autologous peripheral blood stem cell harvest and transplantation after splenectomy in a patient with multiple myeloma with hereditary spherocytosis Daisuke FURUYA1,4, Rikio SUZUKI1,4, Jun AMAKI1, Daisuke OGIYA1, Hiromichi MURAYAMA1,2, Hidetsugu KAWAI1, Akifumi ICHIKI1,3, Sawako SHIRAIWA1, Shohei KAWAKAMI1, Kaito HARADA1, Yoshiaki OGAWA1, Hiroshi KAWADA1 and Kiyoshi ANDO1 Hereditary spherocytosis (HS) is the most common inherited red cell membrane disorder worldwide. We herein report a 58-year-old male HS patient with mild splenomegaly who developed symptomatic multiple myeloma (MM). Autologous stem cell transplantation (ASCT) was considered to be adopted against MM, although there was a possibility of splenic rupture following stem cell mobilization. Therefore, splenectomy was performed prior to stem cell harvest, and he was able to safely mobilize sufficient CD34+ cells with G-CSF and plerixafor and undergo ASCT. This case suggests that stem cell mobilization after splenectomy is safe and effective in HS patients complicated with malignancies. Key words: multiple myeloma, hereditary spherocytosis, splenectomy, autologous peripheral blood stem cell harvest Introduction Consolidation with melphalan-based HDT followed by ASCT is still the standard treatment option for transplant-eligible Multiple myeloma (MM) is characterized by clonal prolifera- patients with MM, leading to higher complete response rates tion of abnormal plasma cells in the bone marrow (BM) micro- and increased progression-free survival and overall survival environment, monoclonal protein in the blood and/or urine, compared with conventional chemotherapy regimens [2]. bone lesions, and immunodeficiency [1]. In recent years, the Importantly, the emergence of novel agent-based therapy introduction of high-dose chemotherapy (HDT) and autol- combined with ASCT has revolutionized MM therapy [2].